---
layout: default
title: Alpha -Tocopherol Succinate D- Alpha Lipoic Acid A
parent: Model Prediction Only (L5)
nav_order: 258
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Succinate D- Alpha Lipoic Acid A
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Multi-Vitamin Mineral Formula: Assessment Report Cannot Be Completed (Lack of TxGNN Prediction Results)

## One-Sentence Summary

This product is a multi-vitamin and mineral supplement containing 20 active ingredients (including fat-soluble vitamins A, D, E, the complete B-complex vitamins, vitamin C, and micronutrients and antioxidants such as selenium, zinc, magnesium, manganese, chromium, copper, Lutein, and Alpha Lipoic Acid).
The TxGNN model failed to generate any predicted indications for this multi-ingredient formula because this formulation is a multi-component mixture without matching DrugBank IDs, **and a standard drug repurposing analysis workflow cannot be conducted at this time**.
Since prediction results are lacking, there is no approval record in Taiwan, and all safety data are missing, this assessment is a case of **insufficient data, no conclusion possible**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No record (not approved in Taiwan) |
| Predicted New Indications | **None** (TxGNN did not generate predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | **Cannot be graded** (no predictions, no trials, no literature) |
| Taiwan Market Status | ✗ Not marketed |
| Total Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why Prediction Analysis Cannot Be Conducted?

This candidate is not a single-molecule drug but a complex formulation composed of 20 ingredients:

> **Fat-Soluble Vitamins**: Vitamin A, Cholecalciferol (D3), D-α-Tocopherol Succinate (E)
>
> **Water-Soluble Vitamins (Complete B-Complex + C)**: Thiamine (B1), Riboflavin (B2), Niacinamide (B3), Calcium Pantothenate (B5), Pyridoxine HCl (B6), Cyanocobalamin (B12), Folic Acid, Biotin, Ascorbic Acid (C)
>
> **Minerals and Trace Elements**: Magnesium Oxide, Zinc Oxide, Cupric Sulfate (copper), Selenium, Manganese, Chromium
>
> **Antioxidants**: Lutein, Alpha Lipoic Acid

The TxGNN model uses a single DrugBank ID as a node for knowledge graph inference. Complex formulations lack a corresponding DrugBank ID, which prevents the model from inputting node embedding vectors, **resulting in empty prediction results**.

Such formulations are typically positioned as "health supplements" or "medical foods," and their indication assessment framework differs from that of single-chemical drugs. The TxGNN architecture is not designed for this type of complex formulation. This assessment result represents an expected system limitation rather than a data error.

---

## Clinical Trial Evidence

Currently, no relevant clinical trial records are available (the assessment target is the complex formulation as a whole; individual component literature is outside the scope of this report).

---

## Literature Evidence

Currently, no relevant literature is available for assessment (reason as above).

---

## Taiwan Market Information

This product has no approval record in Taiwan (`market_status: Not marketed`, `total_licenses: 0`). Possible scenarios are as follows:

1. Applied through food or health supplement pathway, not approved via the drug pathway
2. No Taiwan drug approval certificate has yet been submitted
3. Component data integration error, resulting in zero query results

It is recommended to verify the status of each component's raw material or finished drug formulation directly through the [Taiwan FDA Drug Query System](https://www.fda.gov.tw/).

---

## Safety Considerations

All safety data for this product (warnings, contraindications, drug-drug interactions) are shown as data missing, and DDI queries have not found corresponding results.

> Please refer to each component's package insert or reference the DrugBank individual component page for safety information.
>
> Special attention: Fat-soluble vitamins (A, D, E) have a risk of cumulative toxicity, and serum concentration monitoring is required when used at high doses.

---

## Conclusions and Next Steps

**Decision: Hold**

**Rationale:**
This product is a multi-component complex formulation; the TxGNN prediction engine cannot process this type of input, Taiwan has no approval record, and all safety data are missing. Currently, this does not meet the basic conditions for conducting a drug repurposing assessment.

**To proceed further, the following data need to be supplemented:**

- **Clarify assessment scope**: Confirm whether the assessment is needed for the complex formulation as a whole, or if it should be broken down into individual components for separate TxGNN evaluation (latter recommended)
- **Obtain DrugBank IDs**: For each component (such as Alpha Lipoic Acid, Lutein, Cholecalciferol, etc.), separately map to DrugBank nodes, then execute predictions one by one
- **Confirm regulatory positioning**: Clarify whether this formulation in Taiwan should follow the drug pathway (Taiwan FDA) or special nutrition food pathway (ROC Department of Health, National Health Administration)
- **Supplement MOA data**: If the target is a specific ingredient (such as Alpha Lipoic Acid for diabetic neuropathy), individual DrugBank API queries are required to obtain MOA
- **Complete safety data**: Download package inserts PDF for each major ingredient and parse warnings and contraindications (priority: Vitamin A, Cholecalciferol, Selenium)

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

